These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37558720)

  • 1. Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer.
    Marisi G; Azzali I; Passardi A; Rebuzzi F; Bartolini G; Urbini M; Canale M; Molinari C; Matteucci L; Sullo FG; Debonis SA; Gallio C; Gallo G; Frassineti GL; Ulivi P
    Sci Rep; 2023 Aug; 13(1):12921. PubMed ID: 37558720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.
    Ulivi P; Scarpi E; Passardi A; Marisi G; Calistri D; Zoli W; Del Re M; Frassineti GL; Tassinari D; Tamberi S; Vertogen B; Amadori D
    J Transl Med; 2015 Aug; 13():258. PubMed ID: 26259598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
    Di Salvatore M; Pietrantonio F; Orlandi A; Del Re M; Berenato R; Rossi E; Caporale M; Guarino D; Martinetti A; Basso M; Mennitto R; Santonocito C; Mennitto A; Schinzari G; Bossi I; Capoluongo E; Danesi R; de Braud F; Barone C
    Oncotarget; 2017 Mar; 8(10):16887-16898. PubMed ID: 28129643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
    Formica V; Palmirotta R; Del Monte G; Savonarola A; Ludovici G; De Marchis ML; Grenga I; Schirru M; Guadagni F; Roselli M
    Int J Colorectal Dis; 2011 Feb; 26(2):143-51. PubMed ID: 21188390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
    Loupakis F; Cremolini C; Yang D; Salvatore L; Zhang W; Wakatsuki T; Bohanes P; Schirripa M; Benhaim L; Lonardi S; Antoniotti C; Aprile G; Graziano F; Ruzzo A; Lucchesi S; Ronzoni M; De Vita F; Tonini G; Falcone A; Lenz HJ
    PLoS One; 2013; 8(7):e66774. PubMed ID: 23861747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab.
    Marisi G; Scarpi E; Passardi A; Nanni O; Ragazzini A; Valgiusti M; Casadei Gardini A; Neri LM; Frassineti GL; Amadori D; Ulivi P
    Sci Rep; 2017 May; 7(1):1293. PubMed ID: 28465540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
    Osumi H; Shinozaki E; Ooki A; Wakatsuki T; Kamiimabeppu D; Sato T; Nakayama I; Ogura M; Takahari D; Chin K; Yamaguchi K
    Cancer Med; 2021 Jan; 10(2):615-625. PubMed ID: 33347731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
    Suenaga M; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Yamaguchi T; Lenz HJ
    Int J Cancer; 2019 May; 144(10):2567-2577. PubMed ID: 30411783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.
    Gardini AC; Faloppi L; Aprile G; Brunetti O; Caparello C; Corbelli J; Chessa L; Bruno D; Ercolani G; Leonetti A; Stefano G; Farella N; Foschi FG; Lanzi A; Dadduzio V; Marisi G; Masi G; Negri FV; Pagan F; Santini D; Scarpi E; Silletta M; Silvestris N; Tamburini E; Tassinari D; Vivaldi C; Gentilucci UV; Zagonel V; Calvetti L; Cascinu S; Frassineti GL; Scartozzi M
    Tumori; 2018 Dec; 104(6):476-479. PubMed ID: 29739298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.
    Ulivi P; Scarpi E; Chiadini E; Marisi G; Valgiusti M; Capelli L; Casadei Gardini A; Monti M; Ruscelli S; Frassineti GL; Calistri D; Amadori D; Passardi A
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28598398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.
    Hansen TF; Christensen Rd; Andersen RF; Garm Spindler KL; Johnsson A; Jakobsen A
    Int J Colorectal Dis; 2012 Jun; 27(6):715-20. PubMed ID: 22139032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
    Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
    Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G).
    Izawa N; Shitara K; Yonesaka K; Yamanaka T; Yoshino T; Sunakawa Y; Masuishi T; Denda T; Yamazaki K; Moriwaki T; Okuda H; Kondoh C; Nishina T; Makiyama A; Baba H; Yamaguchi H; Nakamura M; Hyodo I; Muro K; Nakajima TE
    Target Oncol; 2020 Oct; 15(5):623-633. PubMed ID: 32960408
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Papachristos A; Kemos P; Katsila T; Panoilia E; Patrinos GP; Kalofonos H; Sivolapenko GB
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
    Gerger A; El-Khoueiry A; Zhang W; Yang D; Singh H; Bohanes P; Ning Y; Winder T; Labonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; Absenger G; Lenz HJ
    Clin Cancer Res; 2011 Sep; 17(17):5783-92. PubMed ID: 21791631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.
    Casadei Gardini A; Marisi G; Faloppi L; Scarpi E; Foschi FG; Iavarone M; Lauletta G; Corbelli J; Valgiusti M; Facchetti F; Della Corte C; Neri LM; Tamberi S; Cascinu S; Scartozzi M; Amadori D; Nanni O; Tenti E; Ulivi P; Frassineti GL
    Oncotarget; 2016 May; 7(19):27988-99. PubMed ID: 27058899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
    Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
    Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.